Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
38.9M
-
Shares change
-
-336K
-
Total reported value, excl. options
-
$1.17B
-
Value change
-
-$6.52M
-
Number of buys
-
54
-
Number of sells
-
-44
-
Price
-
$29.96
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q3 2021
125 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q3 2021.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9M shares
of 76.6M outstanding shares and own 50.75% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4.72M shares), Redmile Group, LLC (3.09M shares), BlackRock Inc. (2.48M shares), BAKER BROS. ADVISORS LP (2.45M shares), TRV GP III, LLC (2.42M shares), VANGUARD GROUP INC (1.98M shares), STATE STREET CORP (1.63M shares), Bain Capital Life Sciences Investors, LLC (1.28M shares), WELLINGTON MANAGEMENT GROUP LLP (1.23M shares), and BOXER CAPITAL, LLC (1.22M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.